The biotechnology sector has faced notable challenges, particularly for preclinical companies, which have seen a 76% decline in value from 2023 to 2024. Despite this downturn, some analysts suggest that opportunities may still exist for selective biotech investments, especially for those willing to hold through the current market conditions. In 2024, the XBI ETF, which includes approximately 140 biotech companies, remained flat overall; however, 42% of these companies experienced gains of over 20%, while 8.7% suffered losses exceeding 50%. This mixed performance highlights the importance of strategic selection in biotech investments. Experts emphasize the psychological aspects of trading, asserting that patience and emotional discipline are critical for success in a volatile market.